

Christopher H. Schott

Partner

Washington, D.C.

Biography

Christopher H. Schott advises clients in the pharmaceutical industry in connection with drug price reporting and other compliance obligations. His practice focuses on the Medicaid, Medicare, and 340B Drug Pricing programs.

Chris helps pharmaceutical manufacturers apply price reporting and compliance requirements under these Department of Health & Human Services (HHS) programs to their particular business models and commercial approaches, both in terms of ongoing compliance through the development of methodologies and reasonable assumptions, as well as with respect to evaluating specific commercial pricing or contracting strategies and initiatives. Chris also assists pharmaceutical manufacturers that seek to engage with federal regulators regarding these programs, whether as to public policy proposals generally, through comment drafting and in-person advocacy, or where a manufacturer seeks guidance regarding specific commercial proposals and how the regulators may view those proposals under program standards. He also supports manufacturers in connection with state price reporting obligations.

Chris translates this regulatory knowledge into more broad commercial support for pharmaceutical manufacturers. He regularly helps clients evaluate the



Phone

+1 202 637 5467

Fax

+1 202 637 5910

Email

christopher.schott@hoganlovells.com

Languages

English
German

Practices

Health Law
Pharmaceuticals and Biotechnology
Regulatory
Government Relations and Public
Affairs

Industries

Life Sciences and Health Care

impact of HHS program requirements on proposed M&A transactions and advises on due diligence matters and the post-closing transition of regulatory responsibilities under these programs. Chris also regularly advises pharmaceutical manufacturers regarding industry-specific price reporting aspects of their periodic reporting obligations under the U.S. federal securities laws.

Prior to joining Hogan Lovells, Chris was an associate at a leading national law firm, where he represented Wall Street financial institutions and investment banks. Chris was employed in the telecommunication and information technology sectors before and while attending the George Washington University Law School.

In law school, Chris was a George Washington Scholar and a member of *The George Washington International Law Review*. He is a recipient of the law school's Richard L. Teberg Award for Excellence in securities law.

Awards and rankings

- Healthcare: Life Sciences, *Legal 500 US*, 2018

Latest thinking and events

- Insights
 - CMS Medicaid initiative allows states to limit drug coverage, keep manufacturer rebate obligations
- Events
 - Boston Compliance Forum 2019
- Sponsorships and Speaking Engagements
 - Federal Pricing and Reporting conference
- Sponsorships and Speaking Engagements
 - 2019 Medicaid Drug Rebate Program Summit
- Insights
 - Senate Finance Committee Releases Details of Drug

Areas of focus

Pharmaceuticals and Biotechnology
Cell, Tissue, and Gene Therapies

Education and admissions

Education

J.D., The George Washington University Law School, with high honors, 2005

B.A., University of Maryland, 1997

Bar admissions and qualifications

District of Columbia
Maryland

Pricing Bill *Life Sciences & Health Care Alert*

- Hogan Lovells Publications
 - MDRP and the U.S. territories: Manufacturer rebate obligations, but no mandatory coverage, in case of a section 1115 waiver?